Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EPS (Weighted Average and Diluted) (2021 - 2025)

ARS Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.42 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 182.35% year-over-year to -$0.42; the TTM value through Dec 2025 reached -$1.74, down 2275.0%, while the annual FY2025 figure was -$1.74, 2275.0% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.42 at ARS Pharmaceuticals, up from -$0.52 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.19 in Q4 2021 and bottomed at -$0.65 in Q3 2021.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.19 (2024), against an average of -$0.05.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 66.54% in 2022 before it plummeted 246.15% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.19 in 2021, then dropped by 25.21% to $0.89 in 2022, then tumbled by 45.86% to $0.48 in 2023, then increased by 5.85% to $0.51 in 2024, then plummeted by 182.35% to -$0.42 in 2025.
  • Per Business Quant, the three most recent readings for SPRY's EPS (Weighted Average and Diluted) are -$0.42 (Q4 2025), -$0.52 (Q3 2025), and -$0.45 (Q2 2025).